Travere Therapeutics (TVTX) Tops Q4 EPS by 17c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of ($0.47), $0.17 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $74.79 million versus the consensus estimate of $71.08 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Worthington Industries (WOR) Misses Q4 EPS by 9c
• Zhipu Said To Mull Multibillion-dollar Share Sale In Hong Kong - Bloomberg